InMode Ltd.’s (NASDAQ:INMD) Quiet Period To End on September 17th

InMode’s (NASDAQ:INMD) quiet period will end on Tuesday, September 17th. InMode had issued 5,000,000 shares in its initial public offering on August 8th. The total size of the offering was $70,000,000 based on an initial share price of $14.00. During InMode’s quiet period, insiders and underwriters that worked on the IPO are prevented from issuing any research reports or earnings estimates for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company’s quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

A number of research firms have recently issued reports on INMD. Robert W. Baird began coverage on shares of InMode in a research report on Tuesday, September 3rd. They issued an “outperform” rating and a $27.00 price target for the company. Canaccord Genuity began coverage on shares of InMode in a research report on Tuesday, September 3rd. They issued a “buy” rating and a $30.00 price target for the company. Barclays began coverage on shares of InMode in a research report on Tuesday, September 3rd. They issued an “overweight” rating and a $27.00 price target for the company. Finally, UBS Group began coverage on shares of InMode in a research report on Tuesday, September 3rd. They issued a “buy” rating and a $28.00 price target for the company.

NASDAQ INMD opened at $27.53 on Tuesday. InMode has a 52-week low of $13.06 and a 52-week high of $29.38.

InMode (NASDAQ:INMD) last posted its quarterly earnings results on Tuesday, August 13th. The healthcare company reported $0.45 earnings per share (EPS) for the quarter. The company had revenue of $38.80 million during the quarter. On average, research analysts expect that InMode will post 1.38 EPS for the current fiscal year.

About InMode

InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radio frequency technologies. The company offers minimally-invasive aesthetic medical products for procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments.

See Also: What are the benefits of a portfolio tracker?

Receive News & Ratings for InMode Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InMode and related companies with MarketBeat.com's FREE daily email newsletter.